BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

30 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

14 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

10 نوفمبر 2022 07:00:04 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

27 أكتوبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

05 أكتوبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

07 سبتمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

09 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

03 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

26 يوليو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

05 يوليو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

07 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

20 مايو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

09 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

05 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

03 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

26 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

19 أبريل 2022 07:05:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

19 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

06 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

10 مارس 2022 07:04:55 بحسب Nasdaq GlobeNewswire